The FDA’s 2027 budget proposal outlined a potential new “optional, risk-based” expedited Investigational New Drug pathway that would allow some experimental drugs to enter U.S. Phase 1 testing based on existing preclinical data without animal confirmation. The proposal would need congressional action, but the framing targets earlier clinical initiation while lowering development burden and costs. In parallel, Takeda terminated its co-development partnership with Denali Therapeutics and returned full rights to DNL593, an investigational frontotemporal dementia-granulin (FTD-GRN) candidate. Denali said the move was strategic and not tied to efficacy or safety, and expects to report Phase 1/2 trial results by end of 2026. Taken together, the items highlight a dual-track environment: regulators exploring ways to speed early trials while sponsors continue to reshuffle assets when development timelines and strategic fit shift.